The company said revenue for Q2 2024 was $4.8 billion, flat as reported, and up 1% on an Organic basis. Net income margin was 8.9% (versus 8.7% a year earlier), and Adjusted EBIT margin was 15.3% (versus 14.8%).

1. 01

   The company said revenue for Q2 2024 was $4.8 billion, flat as reported, and up 1% on an Organic basis. Net income margin was 8.9% (versus 8.7% a year earlier), and Adjusted EBIT margin was 15.3% (versus 14.8%).

2. 02

   GE HealthCare said net income attributable to GE HealthCare for Q2 was $428 million (versus $418 million a year earlier), diluted EPS was $0.93 (versus $0.91), and Adjusted EPS was $1.00 (versus $0.92). The company cited improved EBIT and lower interest expense as reflected in both EPS measures.

3. 03

   The company said cash from operating activities for Q2 was $(119) million (versus $(67) million a year earlier), and free cash flow was $(182) million (versus $(136) million). For the 6 months ended June, cash from operating activities was $300 million and free cash flow was $92 million.

4. 04

   The company adjusted its full-year Organic revenue growth outlook to 1% to 2% from the prior outlook of about 4%, citing China market headwinds as the factor. It set its Adjusted EBIT margin outlook at 15.7% to 16.0% (previously 15.6% to 15.9%).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.